Literature DB >> 15614146

Reduced-intensity allogeneic hematopoietic stem-cell transplantation as an immunotherapy for metastatic colorectal cancer.

Rie Kojima1, Masahiro Kami, Akiko Hori, Naoko Murashige, Mutsuko Ohnishi, Sung-Won Kim, Tamae Hamaki, Yukiko Kishi, Yutaka Tsutsumi, Nobuo Masauzi, Yuji Heike, Shin-Ichiro Mori, Kazuhiko Kobayashi, Shigeru Masuo, Ryuji Tanosaki, Yoichi Takaue.   

Abstract

BACKGROUND: Allogeneic stem-cell transplantation (allo-SCT) can induce curative graft-versus-leukemia reactions for hematologic malignancies through allogeneic immunity. Because the gastrointestinal tract is a target of graft-versus-host disease (GvHD), colorectal cancer might be a candidate for allo-SCT.
METHODS: Four patients with metastatic colorectal cancer underwent reduced-intensity stem-cell transplantation (RIST) in the National Cancer Center Hospital between July 2002 and February 2003. Three patients received transplants from an human leukocyte antigen (HLA)-identical related donor, and the remaining patient received selected CD34-positive cells from a two-loci HLA-mismatched donor. The basis of preparative regimen was busulfan 4 mg/kg for 2 days and fludarabine 25 mg/kg for 6 days.
RESULTS: All the patients tolerated the preparative regimen and achieved engraftment without significant toxicities. All developed acute or chronic GvHD. Although serum levels of CA19-9 and carcinoembryonic antigen were transiently elevated after RIST in all the patients, the levels subsequently decreased below the levels from before RIST in all but one patient. Three had measurable lesions before RIST, one achieved partial response, and the others stable disease, which was durable for 120 and 60 days. Three patients died; the causes of death were progressive disease, GvHD, and accident. Postmortem examination was obtained for two patients; in one patient, the peritoneal metastatic lesions macroscopically disappeared, and in the other patient, the supraclavicular lymph node disappeared while the other measurable lesions remained stable.
CONCLUSIONS: All the patients showed some evidence suggesting the presence of a graft-versus-tumor effect for colorectal cancer, which should be confirmed in a future prospective trial.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15614146     DOI: 10.1097/01.tp.0000146194.36297.4e

Source DB:  PubMed          Journal:  Transplantation        ISSN: 0041-1337            Impact factor:   4.939


  6 in total

1.  Graft-versus-tumor effect after reduced-intensity allogeneic hematopoietic stem cell transplantation in a patient with advanced colon cancer.

Authors:  Satoshi Hashino; Sumiko Kobayashi; Mutsumi Takahata; Masahiro Onozawa; Masao Nakagawa; Takahito Kawamura; Fumie Fujisawa; Koh Izumiyama; Kaoru Kahata; Takeshi Kondo; Masahiro Asaka
Journal:  Int J Clin Oncol       Date:  2008-05-08       Impact factor: 3.402

2.  Immunotherapy of Metastatic Colorectal Cancer: Prevailing Challenges and New Perspectives.

Authors:  Timothy J Zumwalt; Ajay Goel
Journal:  Curr Colorectal Cancer Rep       Date:  2015-06-29

Review 3.  Stem cells in clinical practice: applications and warnings.

Authors:  Daniele Lodi; Tommaso Iannitti; Beniamino Palmieri
Journal:  J Exp Clin Cancer Res       Date:  2011-01-17

4.  Stem cell Transplantation for Eradication of Minimal PAncreatic Cancer persisting after surgical Excision (STEM PACE Trial, ISRCTN47877138): study protocol for a phase II study.

Authors:  Friedrich H Schmitz-Winnenthal; Thomas Schmidt; Monika Lehmann; Philipp Beckhove; Meinhard Kieser; Anthony D Ho; Peter Dreger; Markus W Büchler
Journal:  BMC Cancer       Date:  2014-03-10       Impact factor: 4.430

5.  Safety and Efficacy of Transplantation with Allogeneic Skin Tumors to Treat Chemically-Induced Skin Tumors in Mice.

Authors:  Zhiwei Zhang; Hua Sun; Jianhua Zhang; Chunlei Ge; Suwei Dong; Zhen Li; Ruilei Li; Xiaodan Chen; Mei Li; Yun Chen; Yingying Zou; Zhongyi Qian; Lei Yang; Jinyan Yang; Zhitao Zhu; Zhimin Liu; Xin Song
Journal:  Med Sci Monit       Date:  2016-09-02

Review 6.  Stem Cell Applications for Treatment of Cancer and Autoimmune Diseases: Its Promises, Obstacles, and Future Perspectives.

Authors:  Yousef M Hawsawi; Faisal Al-Zahrani; Charalampos Harris Mavromatis; Mohammed A Baghdadi; Shalini Saggu; Atif Abdulwahab A Oyouni
Journal:  Technol Cancer Res Treat       Date:  2018-01-01
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.